Array BioPharma (ARRY) Price Target Increased to $13.00 by Analysts at Jefferies Group


The firm presently has a "buy" rating on the biopharmaceutical company's stock. Jefferies Group's price objective would indicate a potential upside of 5.95% from the company's previous close.



from Biotech News